EP Patent

EP1553940A1 — Parenteral formulations containing a rapamycin hydroxyester

Assigned to Wyeth LLC · Expires 2005-07-20 · 21y expired

What this patent protects

This invention provides parenteral formulations of rapamycin 42-ester with 3-hydroxy-2(hydroxymethyl)-2-methylpropionic acid (CCI-779).

USPTO Abstract

This invention provides parenteral formulations of rapamycin 42-ester with 3-hydroxy-2(hydroxymethyl)-2-methylpropionic acid (CCI-779).

Drugs covered by this patent

Patent Metadata

Patent number
EP1553940A1
Jurisdiction
EP
Classification
—
Expires
2005-07-20
Drug substance claim
No
Drug product claim
No
Assignee
Wyeth LLC
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.